icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
Back grey_arrow_rt.gif
Factors associated with rapid eGFR decline while receiving TDF and/or ATV
  Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
Hamzah L1,6, Jose S2, Jones R3, Williams D4, Chadwick D5, Phillips A2, Sabin C2, Post F6 1King’s College London, 2University College London, 3Chelsea and Westminster NHS Foundation Trust, 4Brighton and Sussex University Hospitals NHS Trust, 5South Tees Hospitals NHS Foundation Trust
6King’s College Hospital NHS Foundation Trust, United Kingdom


from Jules: Patients on atazanavir (Reyataz) in this study includes both those on boosted ATV or unboosted, they were lumped together - they did not ask whether unboosted ATV was associated with decline. Whether ATV unboosted without Cobi or RTV is associated or not with true GFR decline has not been studied very much but these 2 studies found unboosted ATV was not associated with GFR decline for the average person, this does not exclude that some patients might experience GFR decline, we need better studies to more reliably answer this question....
Atazanavir & Creatinine - (02/26/17)